Obsidian Therapeutics Completes Merger With Galera Therapeutics

Obsidian Therapeutics has completed its merger with Galera Therapeutics and closed a previously announced oversubscribed $350 million private placement, significantly strengthening its balance sheet as it advances its engineered tumor-infiltrating lymphocyte (TIL) cell therapy pipeline toward key clinical milestones.

The combined company will operate as Obsidian Therapeutics Inc., with shares expected to begin trading on the Nasdaq on Aug. 4, 2026, under the ticker symbol OBX.

Read more at City Biz